|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This region contains two binding sites for a protein, estrogen receptor factor 1 (ERF-1), which is expressed in ER-positive breast carcinomas.
|
7891714 |
1995 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These results indicate that ERF-1 expression represents a common mechanism of ER regulation in hormonally responsive carcinomas.
|
7891714 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tcfap2b and Tcfap2c map to mouse chromosomes 1A2-4 and 2H3-4, respectively, while TFAP2B and TFAP2C map to human chromosomes 6p12 and 20q13.2, the latter being a region that is frequently amplified in breast carcinoma.
|
8661133 |
1996 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given the central role of ER expression in breast carcinoma biology, ERF-1 is likely to regulate expression of a set of genes characteristic of the hormonally-responsive breast cancer phenotype.
|
9113991 |
1997 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERF-1 protein was purified from the ER-positive breast carcinoma cell line, MCF7, utilizing ion exchange and DNA affinity chromatography.
|
9113991 |
1997 |
|
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The ERF-1 transcription factor was previously shown to be involved in the regulation of estrogen receptor (ER) gene transcription in hormonally responsive breast and endometrial carcinomas.
|
9113991 |
1997 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression pattern of one novel gene, DEME -6, correlated with expression of ER and ERF -1/ AP -2gamma in a panel of breast carcinoma cell lines.
|
9461476 |
1998 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Other genes that were highly ranked for their expression in ACC were those encoding the transcription factors SOX4 and AP-2 gamma, the latter of which also was overexpressed in ACC relative to 175 other carcinomas from 10 anatomical sites that we had previously profiled.
|
12368205 |
2002 |
|
Agenesis of corpus callosum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Other genes that were highly ranked for their expression in ACC were those encoding the transcription factors SOX4 and AP-2 gamma, the latter of which also was overexpressed in ACC relative to 175 other carcinomas from 10 anatomical sites that we had previously profiled.
|
12368205 |
2002 |
|
Aplasia Cutis Congenita
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Other genes that were highly ranked for their expression in ACC were those encoding the transcription factors SOX4 and AP-2 gamma, the latter of which also was overexpressed in ACC relative to 175 other carcinomas from 10 anatomical sites that we had previously profiled.
|
12368205 |
2002 |
|
Myeloid neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.
|
11996793 |
2002 |
|
Mammary Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
TOP1, TFAP2C, and (particularly) NCOA3 may be prognostic indicators for patients with breast tumors.
|
12833450 |
2003 |
|
Mammary Neoplasms
|
0.050 |
Biomarker
|
group |
LHGDN |
TOP1, TFAP2C, and (particularly) NCOA3 may be prognostic indicators for patients with breast tumors.
|
12833450 |
2003 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription factor activator protein-2gamma (TFAP2C, AP-2gamma) was reported previously in extraembryonic ectoderm and breast carcinomas but not in the testis.
|
15623634 |
2004 |
|
Mammary Neoplasms
|
0.050 |
AlteredExpression
|
group |
LHGDN |
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
|
15569994 |
2004 |
|
Mammary Neoplasms
|
0.050 |
AlteredExpression
|
group |
LHGDN |
Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region.
|
14565844 |
2004 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression patterns of the translation mechanism, namely of the elongation factors eEF1A1 and eEF1A2, and of the termination factors eRF1 and eRF3, were studied in the breast cancer cell line MCF-7 by real-time quantitative reverse transcription-polymerase chain reaction after a 24-h treatment with NaBu and TSA.
|
15843208 |
2005 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression patterns of the translation mechanism, namely of the elongation factors eEF1A1 and eEF1A2, and of the termination factors eRF1 and eRF3, were studied in the breast cancer cell line MCF-7 by real-time quantitative reverse transcription-polymerase chain reaction after a 24-h treatment with NaBu and TSA.
|
15843208 |
2005 |
|
Fibroid Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Activating transcription factor 3, patched homolog (Drosophila), homeo box A5, death-associated protein kinase 1, and retinoic acid receptor responder 3 were downregulated, and excision repair crosscomplementing 3, transcription factor AP-2 gamma and protein kinase C beta 1 were upregulated in fibroids.
|
15940248 |
2005 |
|
Uterine Fibroids
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Activating transcription factor 3, patched homolog (Drosophila), homeo box A5, death-associated protein kinase 1, and retinoic acid receptor responder 3 were downregulated, and excision repair crosscomplementing 3, transcription factor AP-2 gamma and protein kinase C beta 1 were upregulated in fibroids.
|
15940248 |
2005 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found a significant association between T-ALL oncogenic subgroups and ectopic expression of a limited set of genes, including several developmental genes, namely HOXA, TLX1, TLX3, NKX3-1, SIX6, and TFAP2C.
|
15774621 |
2005 |
|
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
Methylation status of the 32 randomly selected and 16 potential tumor-related genes was analyzed in 10 primary gastric cancers, and 42 genes (ABHD9, ADFP, ALDH1A3, ANXA5, AREG, BDNF, BMP7, CAV1, CDH2, CLDN3, CTSL, EEF1A2, F2R, FADS1, FSD1, FST, FYN, GPR54, GREM1, IGFBP3, IGFBP7, IRS2, KISS1, MARK1, MLF1, MSX1, MTSS1, NT5E, PAX6, PLAGL1, PLAU, PPIC, RBP4, RORA, SCRN1, TBX3, TFAP2C, TNFSF9, ULBP2, WIF1, ZNF177 and ZNF559) were methylated in at least one primary gastric cancer.
|
16367923 |
2006 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that TFAP2C is a central control gene of hormone response and is a novel therapeutic target in the design of new drug treatments for breast cancer.
|
17875680 |
2007 |